Council of Scientific and Industrial Research on September 20 informed that Drugs Controller General of India has approved CSIR's paper-based testing kit called Feluda for COVID-19. CSIR, Director General S Mande said, "Our Delhi CSIR lab's been working on studying CRISPR-Cas immunity. They have experience of working in this particular area before COVID-19 and could repurpose the thing for COVID and developed a paper-based testing kit called Feluda and got formal approval from DCGA. Mande further explained the functioning of the paper based test. "It's different as RTPCR detects RNA and amplifies it using a polymerase chain reaction that is costly. This paper-based test also detects RNA but by a CRISPR guided system. The paper lights up if there is any virus RNA to show a sample is positive, in 45 minutes," he added.
As clinical trials of different COVID-19 vaccines are in various phases across the globe, an AIIMS (All India Institute of Medical Sciences) doctor said that if everything goes as planned, people can expect a vaccine as early as the starting of next year. "Phase 2 clinical trial for COVID-19 vaccine is underway in India with a good sample size of more than 600 motivated volunteers. Any vaccine will come by mid-next year, if everything goes as planned," Community Medicine Department head added. On the Sero-survey conducted by Indian Council of Medical Research, Dr. Rai said the survey only shows the direction of infection while testing shows the actual number of infections.
The health ministry has asked AIIMS to designate part of the new emergency wing at its trauma facility, Jai Prakash Narayan Apex Trauma Centre, for setting up of... IndiaTimes Also reported by •Indian Express